- Home
- ALMS vs URGN Comparison
ALMS vs URGN Comparison
Compare ALMS & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALMS
- URGN
- Stock Information
- Founded
- ALMS 2021
- URGN 2004
- Country
- ALMS United States
- URGN United States
- Employees
- ALMS N/A
- URGN N/A
- Industry
- ALMS
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- ALMS
- URGN Health Care
- Exchange
- ALMS NYSE
- URGN Nasdaq
- Market Cap
- ALMS 469.0M
- URGN 465.9M
- IPO Year
- ALMS 2024
- URGN 2017
- Fundamental
- Price
- ALMS $7.41
- URGN $10.19
- Analyst Decision
- ALMS Strong Buy
- URGN Strong Buy
- Analyst Count
- ALMS 6
- URGN 5
- Target Price
- ALMS $29.60
- URGN $44.50
- AVG Volume (30 Days)
- ALMS 121.0K
- URGN 487.3K
- Earning Date
- ALMS 02-15-2025
- URGN 03-13-2025
- Dividend Yield
- ALMS N/A
- URGN N/A
- EPS Growth
- ALMS N/A
- URGN N/A
- EPS
- ALMS N/A
- URGN N/A
- Revenue
- ALMS N/A
- URGN $89,363,000.00
- Revenue This Year
- ALMS N/A
- URGN $12.21
- Revenue Next Year
- ALMS N/A
- URGN $46.19
- P/E Ratio
- ALMS N/A
- URGN N/A
- Revenue Growth
- ALMS N/A
- URGN 15.64
- 52 Week Low
- ALMS $6.75
- URGN $9.78
- 52 Week High
- ALMS $13.53
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- ALMS N/A
- URGN 38.51
- Support Level
- ALMS N/A
- URGN $10.12
- Resistance Level
- ALMS N/A
- URGN $10.91
- Average True Range (ATR)
- ALMS 0.00
- URGN 0.56
- MACD
- ALMS 0.00
- URGN -0.01
- Stochastic Oscillator
- ALMS 0.00
- URGN 20.71
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.